Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up - Time to Buy?

Pacific Biosciences of California logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • PACB shares rose at the open, climbing from a prior close of $1.82 to an opening price of $1.89 and last trading at $1.984.
  • Analyst sentiment remains cautious: the consensus rating is “Reduce”, with a $2.57 price target; three analysts rate the stock Hold and two rate it Sell.
  • The company beat quarterly estimates, reporting a loss of $0.11 per share versus expectations of $0.13 and revenue of $40.56 million versus $39.31 million expected. Its results still included an 81.31% negative net margin.
  • MarketBeat previews the top five stocks to own by December 1st.

Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $1.82, but opened at $1.89. Pacific Biosciences of California shares last traded at $1.9840, with a volume of 1,375,868 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PACB shares. Barclays lifted their target price on shares of Pacific Biosciences of California from $1.25 to $2.00 and gave the stock an "underweight" rating in a research note on Thursday, November 5th. Weiss Ratings upgraded shares of Pacific Biosciences of California from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, October 13th. Wall Street Zen raised shares of Pacific Biosciences of California from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. UBS Group reduced their price objective on shares of Pacific Biosciences of California from $3.05 to $2.70 and set a "neutral" rating for the company in a research note on Monday, November 9th. Finally, Piper Sandler reissued a "neutral" rating and set a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a report on Thursday, November 5th. Three research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and a consensus price target of $2.57.

Get Our Latest Analysis on Pacific Biosciences of California

Pacific Biosciences of California Stock Performance

The firm has a 50 day simple moving average of $2.03 and a 200 day simple moving average of $1.60. The firm has a market cap of $599.26 million, a P/E ratio of -4.56 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 81.31%. The firm had revenue of $40.56 million for the quarter, compared to analysts' expectations of $39.31 million. Sell-side analysts predict that Pacific Biosciences of California, Inc. will post -0.51 EPS for the current fiscal year.

Insider Transactions at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider James Gibson, II sold 661,815 shares of the firm's stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the transaction, the insider directly owned 1,083,848 shares of the company's stock, valued at $3,370,767.28. This trade represents a 37.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pacific Biosciences of California

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Pacific Biosciences of California in the 2nd quarter worth approximately $54,330,000. Bank of America Corp DE purchased a new stake in shares of Pacific Biosciences of California during the 2nd quarter valued at $2,265,000. Hhlr Advisors LTD. purchased a new stake in shares of Pacific Biosciences of California during the 2nd quarter valued at $1,544,000. Bank of New York Mellon Corp purchased a new stake in shares of Pacific Biosciences of California during the 2nd quarter valued at $1,290,000. Finally, Man Group plc bought a new stake in shares of Pacific Biosciences of California during the 2nd quarter worth $1,004,000.

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, or PacBio, develops and sells DNA sequencing systems and related products for life science research and clinical applications. The company is known for its single-molecule real-time (SMRT) sequencing technology, which produces long reads that can help researchers study complex regions of the genome and identify genetic variations. Its portfolio includes HiFi sequencing systems such as the Revio and Vega platforms, along with instruments, consumables, software and services used to prepare, sequence and analyze genetic samples.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pacific Biosciences of California Right Now?

Before you consider Pacific Biosciences of California, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacific Biosciences of California wasn't on the list.

While Pacific Biosciences of California currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines